|
Name |
Penijanthine A
|
Molecular Formula | C27H33NO3 | |
IUPAC Name* |
(1S,2R,5S,7R,8R,11S,14R)-1,2-dimethyl-7-prop-1-en-2-yl-6-oxa-22-azahexacyclo[12.10.0.02,11.05,10.015,23.016,21]tetracosa-9,15(23),16,18,20-pentaene-8,11-diol
|
|
SMILES |
CC(=C)[C@@H]1[C@@H](C=C2[C@@H](O1)CC[C@]3([C@]2(CC[C@@H]4[C@@]3(CC5=C4C6=CC=CC=C6N5)C)O)C)O
|
|
InChI |
InChI=1S/C27H33NO3/c1-15(2)24-21(29)13-18-22(31-24)10-11-26(4)25(3)14-20-23(17(25)9-12-27(18,26)30)16-7-5-6-8-19(16)28-20/h5-8,13,17,21-22,24,28-30H,1,9-12,14H2,2-4H3/t17-,21+,22-,24+,25-,26+,27+/m0/s1
|
|
InChIKey |
WHBHNFDFPCYJCA-PKKYMZQFSA-N
|
|
Synonyms |
Penijanthine A
|
|
CAS | NA | |
PubChem CID | 139585528 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 419.6 | ALogp: | 3.7 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.5 | Aromatic Rings: | 6 |
Heavy Atoms: | 31 | QED Weighted: | 0.558 |
Caco-2 Permeability: | -5.24 | MDCK Permeability: | 0.00001500 |
Pgp-inhibitor: | 0.112 | Pgp-substrate: | 0.842 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.421 |
30% Bioavailability (F30%): | 0.032 |
Blood-Brain-Barrier Penetration (BBB): | 0.557 | Plasma Protein Binding (PPB): | 91.26% |
Volume Distribution (VD): | 2.045 | Fu: | 5.31% |
CYP1A2-inhibitor: | 0.143 | CYP1A2-substrate: | 0.865 |
CYP2C19-inhibitor: | 0.57 | CYP2C19-substrate: | 0.806 |
CYP2C9-inhibitor: | 0.501 | CYP2C9-substrate: | 0.189 |
CYP2D6-inhibitor: | 0.304 | CYP2D6-substrate: | 0.382 |
CYP3A4-inhibitor: | 0.835 | CYP3A4-substrate: | 0.874 |
Clearance (CL): | 5.872 | Half-life (T1/2): | 0.065 |
hERG Blockers: | 0.313 | Human Hepatotoxicity (H-HT): | 0.628 |
Drug-inuced Liver Injury (DILI): | 0.044 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0.976 | Maximum Recommended Daily Dose: | 0.965 |
Skin Sensitization: | 0.091 | Carcinogencity: | 0.901 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
Respiratory Toxicity: | 0.985 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000836 | 0.479 | D0H4JM | 0.286 | ||||
ENC003329 | 0.464 | D01JGV | 0.276 | ||||
ENC003330 | 0.460 | D0U7GP | 0.276 | ||||
ENC001492 | 0.460 | D0K0KH | 0.254 | ||||
ENC001486 | 0.457 | D06AEO | 0.254 | ||||
ENC003834 | 0.439 | D04GJN | 0.250 | ||||
ENC005989 | 0.438 | D0P0HT | 0.242 | ||||
ENC003172 | 0.438 | D08QKJ | 0.240 | ||||
ENC003453 | 0.421 | D06CWH | 0.240 | ||||
ENC002951 | 0.398 | D0I2SD | 0.240 |